Fintel reports that on September 25, 2026, Raymond James initiated coverage of Seaport Therapeutics (NASDAQGS:SPTX) with a Strong Buy recommendation.

Prior to this action, other firms also updated their outlooks on Seaport Therapeutics. On September 10, 2026, HC Wainwright & Co. reiterated its Buy rating, maintaining the recommendation at Buy. Earlier, on August 26, 2026, Jones Trading initiated coverage on the stock with a Buy rating.

As of the current recommendation period starting September 1, 2026, the aggregate analyst sentiment shows a positive outlook. Out of 13 total recommendations, there are 5 strong buy, 6 buy, and 2 hold recommendations, with 0 sell and 0 strong sell recommendations. This represents a positive recommendation percentage of 84.6% and a hold percentage of 15.4%. In the prior recommendation period starting August 1, 2026, there were 11 total recommendations, consisting of 4 strong buy, 5 buy, 2 hold, 0 sell, and 0 strong sell recommendations, representing an 81.8% positive percentage and an 18.2% hold percentage.

Separately, consensus price target data shows a mean target of $37.13 and a median target of $35.70 as of September 15, 2026. This mean target represents an implied change of +72.61%. The prior consensus target mean was also $37.13 as of August 29, 2026, indicating a consensus target revision of 0.00%.

In terms of market performance, Seaport Therapeutics closed at $21.51 on September 25, 2026. The stock closed at $21.12 on September 24, 2026, the session prior to the rating action. Looking at historical performance, the stock experienced a price change of +0.56% over one week, relative to a baseline close of $21.39 on September 18, 2026. Over a one-month period, the stock saw a price change of -13.37% from a baseline close of $24.83 on August 25, 2026.

The company's most recent earnings report was released on August 3, 2026. For this period, Seaport Therapeutics reported an actual EPS of -0.73, compared to an estimated EPS of -0.6256. The actual revenue for the quarter was reported as $0.00, which matched the estimated revenue of $0.00.

Recent analyst actions

Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.

Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.

This story originally appeared on Fintel.